Navigation Links
New International Study Shows Women With Symptomatic Fibroids Delaying Treatment Despite Substantial Burden on Quality of Life
Date:10/29/2008

One in five women suffer from fibroid symptoms at least 5 years before seeking treatment.

LAS VEGAS, Oct. 29 /PRNewswire/ -- At the annual meeting of the American Association of Gynecologic Laparoscopists (AAGL), ETHICON Women's Health & Urology today announced results of a seven-country study measuring the effects of uterine fibroids and associated symptoms on quality of life (QoL). Researchers found that one in five women suffer with symptomatic fibroids for more than 5 years before getting medical treatment. Further, despite diagnosis, more than one-third of women remain untreated -- either surgically or medically -- for their fibroids, which means that many women continue to experience symptoms severe enough to affect QoL.

Uterine fibroids are benign tumors made up of fibrous and muscular tissue in the uterine wall. They occur in one third of women over age thirty and are a major reason for hysterectomy worldwide. Women who have uterine fibroids may experience debilitating symptoms such as abnormal bleeding, pain, pressure in the pelvic region, painful intercourse, frequent urination or infertility.

The CHASM (Cross-Sectional Survey of HRQoL And Symptoms of Myoma) study was sponsored by ETHICON and designed to quantify the fibroid burden on a woman's QoL and to better understand current management of symptomatic fibroids. More than 2,500 adult women experiencing fibroid symptoms with a self-reported physician diagnosis or previous treatment for uterine fibroids were surveyed in the United States, Canada and five European countries. Researchers found that:

-- Overall, 22% of women who have been diagnosed with uterine fibroids

waited at least five years before getting treatment.

-- A substantial percentage of women (almost 45% of those diagnosed and

almost 70% of those with symptoms) have not sought any treatment in the

past year

-- Of those who have sought medical care and been
'/>"/>

SOURCE ETHICON Women?s Health & Urology
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2

Related medicine technology :

1. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
2. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
3. Ozarelix Phase 2 Data Presented at 29th Congress of the Societe Internationale dUrologie
4. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
5. International Expert Group Initiates Largest Multi-center Phase III Trial to Evaluate NeuroAid(TM) in Stroke Recovery
6. Surface Logix Presents Positive Phase 1 Repeat-Dose Trial Data on SLx-4090 at The 16th International Symposium on Drugs Affecting Lipid Metabolism
7. Preclinical Data on Lead MEK Inhibitor, RDEA119, to be Presented at the 2007 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
8. Tumor Growth Inhibition and Pharmacokinetic Profile of NKTR-102 (PEG-Irinotecan) in Multiple Solid Tumors To Be Presented at Upcoming AACR-NCI-EORTC International Conference
9. Preimplantation Genetic Diagnosis International Society Refutes American Society of Reproductive Medicine Opinion - States Preimplantation Genetic Screening is Beneficial When Performed in Experienced Centers
10. Survival Data for Avicenas Amyotrophic Lateral Sclerosis Drug Candidate, AL-02, to be Presented at 18th International Symposium on ALS/MND
11. CEL-SCI CEO to Present at the International Society for Pharmaceutical Engineering 2007 Chesapeake BioShowcase
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... -- Omeros Corporation (NASDAQ: OMER ) today ... to evaluate OMS824 in Huntington,s disease has been ... (FDA). OMS824 selectively inhibits phosphodiesterase 10 (PDE10), an ... to a wide range of diseases that affect ... shown promising results in animal models directly relevant ...
(Date:5/23/2013)... , May 23, 2013  Inhibikase Therapeutics, Inc., ... today that it will present new results on ... industry conference sponsored by the PML Consortium (composed ... JC polyomavirus (JCV) is the causative agent of ... kinase inhibitor in an extended release formulation, can ...
(Date:5/23/2013)... -- InspireMD, Inc. ("InspireMD" or the ... protection stents, today announced new 6-month results from ... trial demonstrating that the MGuard Embolic Protection Stent ... in all-cause mortality in ST segment elevation myocardial ... presented at the InspireMD STEMI Symposium at EuroPCR, ...
Breaking Medicine Technology:Investigational New Drug Application Cleared by FDA for OMS824 in Huntington's Disease 2Investigational New Drug Application Cleared by FDA for OMS824 in Huntington's Disease 3Investigational New Drug Application Cleared by FDA for OMS824 in Huntington's Disease 4Inhibikase Therapeutics to present at Industry Conference on Drug-Induced Progressive Multifocal Leukoencephalopathy (PML) 2InspireMD's MGuard Embolic Protection Stent (EPS) Shows Lower Mortality Rate in STEMI Patients at Six Months Compared to Control Group 2InspireMD's MGuard Embolic Protection Stent (EPS) Shows Lower Mortality Rate in STEMI Patients at Six Months Compared to Control Group 3InspireMD's MGuard Embolic Protection Stent (EPS) Shows Lower Mortality Rate in STEMI Patients at Six Months Compared to Control Group 4InspireMD's MGuard Embolic Protection Stent (EPS) Shows Lower Mortality Rate in STEMI Patients at Six Months Compared to Control Group 5
... Bionovo, Inc. (Nasdaq: BNVI, BNVID), a drug discovery and development ... oncology, today announced that Dr. Isaac Cohen, O.M.D., Chairman and ... Healthcare Conference at 4:00 p.m. ET on Tuesday, September 28, ... Palace hotel in New York City. Interested parties ...
... Sept. 21 Anthera Pharmaceuticals, Inc. (Nasdaq: ... definitive agreements with certain accredited investors in connection with ... Section 4(2) of the Securities Act of 1933, as ... of the transaction, Anthera will receive gross proceeds of ...
Cached Medicine Technology:Bionovo to Present at the JMP Securities Healthcare Conference 2Anthera Pharmaceuticals Announces Pricing of $31.5 Million PIPE Financing 2Anthera Pharmaceuticals Announces Pricing of $31.5 Million PIPE Financing 3Anthera Pharmaceuticals Announces Pricing of $31.5 Million PIPE Financing 4
(Date:5/23/2013)... Sika Sarnafil , the worldwide market leader in ... Systems of Iowa as the Recycling Project of the ... the re-roofing of the SuperTarget retail store in Olathe, ... contractor and one of Target’s Preferred Tier One roofing ... building practices and they are a worthy recipient of ...
(Date:5/23/2013)... Professional Insurance Plans, an independent insurance ... celebrate Fibromyalgia Education and Awareness Month. As a ... country, the agency feels that it is important for ... that affects an estimated 10 million of Americans. , ... definition of Fibromyalgia (FM) is, “a common and complex ...
(Date:5/23/2013)... 23, 2013 Traditionally, laser skin therapy ... on skins of colour, this can be tricky. Based ... 1-1V may be treated safely with most lasers. Darker ... discoloration issues, have been left without recourse. Those who ... “clear” their skin successfully. , Hyperpigmentation occurs ...
(Date:5/23/2013)... , , THURSDAY, May 23 (HealthDay News) -- Statins are ... but the medications also could hamper heart patients, ability ... A small group of overweight or obese people ... taking a 40 milligram daily dose of simvastatin, while ... same exercise regimen did show improvement, found the study ...
(Date:5/23/2013)... PTSD , Soldiers returning home from combat may ... disorder if public support for a war effort is ... shapes the level of distress soldiers feel from the ... two experiments that asked participants to exterminate woodlice in ... actor show either interest or disgust for the act ...
Breaking Medicine News(10 mins):Health News:Sika Sarnafil Announces Recycling Project of the Year Winner 2Health News:Professional Insurance Plans Encourages the Nation to Celebrate Fibromyalgia Education and Awareness Month 2Health News:Vancouver Skin Care Clinic Successfully Clears Pigmentation in Skin of Colour 2Health News:Vancouver Skin Care Clinic Successfully Clears Pigmentation in Skin of Colour 3Health News:Statins May Hamper Workout Results 2Health News:Statins May Hamper Workout Results 3Health News:Link between war support and PTSD, time it late in negotiations and courtship by narcissists 2Health News:Link between war support and PTSD, time it late in negotiations and courtship by narcissists 3
... Spanish . , The PhD, defended ... the Basque Country, proposes a series of recommendations that ... professionals who treat terminal cancer patients. , Autonomy is ... armed with knowledge about the causes of the illness, ...
... talk and ... care about digestive health, WHITE PLAINS, ... advertising campaign for Activia featuring award-winning,actress and passionate self-esteem advocate ... air throughout 2008, Curtis draws attention,to the importance of digestive ...
... Named National, Spokesperson for The Leukemia & Lymphoma Society,s 2008 Light The ... ... March 3 Rob Brown, who stars in the,upcoming drama The Express as ... to win the Heisman,Trophy, is the national spokesperson for The Leukemia & Lymphoma ...
... The Providence Service,Corporation (Nasdaq: PRSC ) today ... its fourth quarter and year ended December 31, 2007,on ... Providence will hold a conference call at 11:00 a.m. ... Thursday, March 13, 2008 to discuss its,financial results and ...
... CEL-SCI CORPORATION,(Amex: CVM ) provided details ... groundbreaking activities currently underway at its,manufacturing facility near ... Multikine(R), the Company,s lead compound, for a pivotal,Phase ... untreated head,and neck cancer patients. The facility, which ...
... ... Hospitals, TEL AVIV, ... digital templating software, will,launch its unique Orthoweb on-line service at the ... in San,Francisco (Booth #349, Hall A)., "This is a real ...
Cached Medicine News:Health News:Factors that enhance autonomy of cancer patients 2Health News:Factors that enhance autonomy of cancer patients 3Health News:Dannon Activia Launches Thought-Provoking Advertising Campaign Featuring Jamie Lee Curtis 2Health News:Dannon Activia Launches Thought-Provoking Advertising Campaign Featuring Jamie Lee Curtis 3Health News:Actor Rob Brown Rushes to Gain Ground Against Blood Cancer 2Health News:Providence Service Corporation to Report Fourth Quarter 2007 Results on Wednesday, March 12th After the Market Closes 2Health News:Providence Service Corporation to Report Fourth Quarter 2007 Results on Wednesday, March 12th After the Market Closes 3Health News:CEL-SCI CORPORATION Announces Results of 2008 Annual Meeting of Shareholders and Provides Update on Ground-breaking Activities Regarding Construction of Manufacturing Facility for Pivotal Phase III Cancer Trial 2Health News:Orthocrat to Launch On-Line Service for Storing and Sharing Pre-Operative Data at AAOS 2
To maintain the conjunctival cul-de-sacs after enucleation or evisceration without hindering lid closure....
To maintain the conjunctival cul-de-sacs after enucleation or evisceration without hindering lid closure....
... coated with a thin layer ... the surface slick as glass ... prevent debris from collecting on ... For partial stenosis. Silicone with ...
With side bite Instrument recommended to catch the polypropylene thread in the nose....
Medicine Products: